4449-42-7

Upstream product

• 31615-99-3 3',5'-dibenzoyl-2'-deoxy-β-L-uridine 
• 4753-02-0 2'-Desoxy-2'-bromouridin 
• 951-78-0 2'-deoxyuridine 
• 1312300-24-5 C₂₁H₃₈N₂O₆Si₂ 
• 1312300-23-4 C₂₁H₃₈N₂O₇Si₂ 
• 58-96-8 L-uridine 
• 21740-23-8 3,5-O-bis(4-chlorobenzoyl)-2-deoxy-α-D-ribofuranosyl chloride 
• 4449-30-3 1-[O³,O⁵-bis-(4-chloro-benzoyl)-α-D-erythro-2-deoxy-pentofuranosyl]-1H-pyrimidine-2,4-dione 
• 88492-31-3 5-Trimethylsilyl-2'-deoxy-α-uridine 

Downstream Products

• 17039-17-7 2-deoxyribofuranose-1-phosphate 
• 66-22-8 uracil 
• 207128-21-0 1-((2S,4R,5S)-4-Fluoro-5-trityloxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione 
• 207128-18-5 1-((2S,4S,5S)-4-Hydroxy-5-trityloxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione 
• 207128-16-3 Methanesulfonic acid (2S,3R,5S)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-2-trityloxymethyl-tetrahydro-furan-3-yl ester 
• 207128-22-1 β-2',3'-dideoxy-3'-fluoro-L-uridine 
• 177365-14-9 β-L-2',3'-dideoxy-3'-fluorocytidine 
• 816429-66-0 5'-O-trityl-2'-deoxy-L-uridine 
• 162239-35-2 5-Iodo-2'-deoxy-L-uridine 
• 128575-79-1 2-chlorophenyl 3'-(2'-deoxyuridylyl) 3-<7β-(triethylsiloxy)cholesteryl> phosphotriester 
• 128548-95-8 2-chlorophenyl 5'-(2'-deoxyuridylyl) 3-<7β-(triethylsiloxy)cholesteryl> phosphotriester 

Relevant academic research and scientific papers

NOVEL 3′-DEOXY-3′-METHYLIDENE- -L-NUCLEOSIDES

The present invention includes novel 3′-deoxy-3′-methylidene-β-L-nucleosides, pharmaceutical composition comprising such compounds, as well as the methods to treat or to prevent viral infections and in particular HBV and/or HIV infections. In accordance with the present invention, there are provided compounds represented by Formula (I), wherein B is selected from A1 and A2;

Methods of manufacture of 2'-deoxy-beta-L-nucleosides

The present invention relates to the synthesis of 2′-deoxy-β-L-thymidine, 2′-deoxy-β-L-uridine and 2′-deoxy-β-L-cytidine, and their derivatives, such as the 3′-O-acyl or 3′,5′-O-diacyl prodrugs, including the 3′-O-L-aminoacyl and 3′,5′-O-L-diaminoacyl prodrugs, and particularly the 3′-O-L-valinyl and 3′,5′-O-L-divalinyl prodrugs.

Ionization of purine nucleosides and nucleotides and their components by 193-nm laser photolysis in aqueous solution: Model studies for oxidative damage of DNA 1

The effect of 20-ns pulses of 193-nm laser light on aqueous solutions of purine bases, (2′-deoxy)nucleosides, and (2′-deoxy)nucleotides was investigated, and monophotonic ionization was observed. Although (deoxy)ribose and (deoxy)ribose phosphates are also ionized by 193-nm light, the photoionization of the (deoxy)nucleosides and -tides takes place predominantly (90%) at the purine moiety, due to the much higher extinction coefficients at 193 nm of the bases as compared to the (deoxy)ribose phosphates. The quantum yields of photoionization (φPl) of the purines are in the range 0.01 to 0.08, based on φ(Cl-) at 193 nm of 0.46. As shown by comparison with data obtained from pulse radiolysis, the ionized purines, i.e., the radical cations, deprotonate in neutral solution, yielding neutral radicals. The radical cation of 1-methylguanosine, produced by photoionization in oxygen-saturated aqueous solution, deprotonates with the rate constant 3.5 × 105 s-1. In the absence of oxygen, the hydrated electrons resulting from the photoionization react with the untransformed purine derivatives to yield the corresponding radical anions. As these are rapidly protonated by water (as concluded from pulse radiolysis), the photoionization in deaerated neutral solution results in two different neutral radicals: a deprotonated radical cation and a protonated radical anion.